Cytokeratin 8 Antibody (KRT8/803), Novus Biologicals™

Cytokeratin 8

0.2mg/mL

Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence

Unconjugated

Mouse

Cancer, Cytoskeleton Markers

10mM PBS and 0.05% BSA with 0.05% Sodium Azide

3856

Recombinant human KRT8 protein

Primary

Store at 4C.

52.5 kDa

KRT8/803

Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 1 - 2 ug/ml

Monoclonal

Purified

RUO

Human

CARD2, CK8, CK-8, CYK8cytokeratin 8, Cytokeratin-8, K2C8, K8cytokeratin-8, keratin 8, keratin, type II cytoskeletal 8, keratin-8, KO, Type-II keratin Kb8

KRT8

IgG1 κ

Protein A or G purified

Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Anti-CK8 is useful for the differentiation of lobular (ring-like, perinuclear) from ductal (peripheral-predominant) carcinoma of the brea